Second-generation antipsychotics are widely used to treat a range of psychiatric disorders in children and adolescents but are frequently associated with significant weight gain and metabolic sequelae. Metformin, an antihyperglycemic agent, is an evidence-based option for mitigating these adverse effects in youth. Despite evidence supporting its efficacy and safety, adjunctive metformin remains underutilized in pediatric patients receiving second-generation antipsychotics.
No takes yet. Share an insight, caveat, or question.
Erin E. Ellington (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: